The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
Developing A Safe Vaccine Against Group A Streptococci
Funder
National Health and Medical Research Council
Funding Amount
$768,530.00
Summary
Group A streptococcus causes 520,000 deaths each year. A safe and effective vaccine is not commercially available. We have identified new protective candidate antigens, and we seek to undertake critical non-human primate studies to provide further proof-of-concept data. This work will underpin commercial decisions by our industry partner (Sanofi Pasteur) leading to human trials and the development of a safe group A streptococcal vaccine for human use.
Anti-inflammatory Compound Development For The Treatment Of Heart Failure With Preserved Ejection Fraction
Funder
National Health and Medical Research Council
Funding Amount
$674,659.00
Summary
Heart failure with preserved ejection fraction (HFpEF) is a highly prevalent and rapidly growing heart condition with no proven effective therapies. We will develop novel drugs to treat HFpEF by focussing on heart scarring and inflammation. We have promising drug candidates that will be developed during the project, and these will be ready for for phase I clinical trial by the end of this grant. The outcome of this study is poised to address the significant unmet medical need.
Development Of A First-in-class Therapeutic For Protecting The Ischemic Heart
Funder
National Health and Medical Research Council
Funding Amount
$926,673.00
Summary
Heart disease is the leading cause of death globally. Heart attacks are the primary cause of death associated with heart disease. We have discovered a drug, Hi1a, that blocks the injury response of the heart when a heart attack happens. There are no other drugs currently available or in the discovery pipeline that address this problem. This proposal will use models of injury to the heart as well as safety studies to help develop Hi1a as a new drug for people who suffer from heart attacks.
Development Of An Extended Release Oral Formulation Of Milrinone For Patients With Advanced Heart Failure
Funder
National Health and Medical Research Council
Funding Amount
$467,083.00
Summary
Heart failure is a debilitating condition associated with frequent hospitalization. Milrinone is an effective intravenous drug used to treat acute deteriorations. Previously, oral milrinone failed because of the lack of availability of appropriate formulations. We have developed an oral formulation which provides stable release of the medication. This application will evaluate the effectiveness of the drug in man and provide the documentation to take the project forward for partnership with indu ....Heart failure is a debilitating condition associated with frequent hospitalization. Milrinone is an effective intravenous drug used to treat acute deteriorations. Previously, oral milrinone failed because of the lack of availability of appropriate formulations. We have developed an oral formulation which provides stable release of the medication. This application will evaluate the effectiveness of the drug in man and provide the documentation to take the project forward for partnership with industry as a means to clinical translation.Read moreRead less
A Non-invasive Fluid Status Monitoring Device For Heart Failure
Funder
National Health and Medical Research Council
Funding Amount
$360,715.00
Summary
Both acute decompensated heart failure (ADHF) and chronic kidney disease (CKD) are characterised by fluid overload. A device to detect this fluid overload in patients at an early stage has the potential to reduce the need for hospitalisation and initiate more timely and aggressive intervention. A prototype device has already been developed and our aim is to further improve on this device and advance to a commercial product.
Peptide Therapeutics For The Treatment Of Autoimmune Diseases: Stability, Delivery And Disposition
Funder
National Health and Medical Research Council
Funding Amount
$368,467.00
Summary
Autoimmune diseases affect around 120 million people worldwide. This project will progress the development of a peptide that suppresses disease-causing autoantigen-specific immune responses without affecting protective responses. Different routes of delivery for this peptide will be evaluated, as well as slow-release formulations that will extend its in vivo lifetime. The outcome will be a patient-friendly form of this therapeutic lead that can be taken forward to preclinical evaluation.
A vitamin-sized capsule, containing gas sensors, is to be fully developed for assessing the state of health and diagnosing the diseases relevant to gastrointestinal tract. The capsule travels along the tract, transmitting information about the gas species generated by the microorganisms of the gut, which is closely associated with the health of the human under surveillance. The information will be invaluable for diagnostics and adjusting the diet to mitigate and cure the diseases of the guts.
Enhanced Deep Brain Stimulation Electrodes For Improved Efficacy In Parkinson’s Disease Therapy
Funder
National Health and Medical Research Council
Funding Amount
$809,940.00
Summary
We are developing an advanced Deep Brain Stimulation system to improve the treatment for Parkinson’s disease. Current devices benefit only half of the patients, due to imprecision in directing the electrical current to the ideal brain targets. Our system aims to deliver the current more selectively. Our implant will contain more and smaller electrodes. We will also use a state-of-the-art stimulator, implantable on the head, with capabilities far beyond the current technology.
Evaluation Of The Safety Of Lead Compounds For Allergic Asthma
Funder
National Health and Medical Research Council
Funding Amount
$310,568.00
Summary
Asthma is one of the most common chronic respiratory diseases in developed countries and is typically treated with corticosteroids which provide symptomatic relief and coarse non-specific treatment of the underlying disease. We are pursuing innovative therapies by targeting a different enzyme, HPGD2S, involved in the inflammatory mechanisms of asthma. We have developed potent, anti-inflammatory drug candidates and aim to profile the safety of these compounds before entering clinical studies.
Fighting Blindness With A Minimally Invasive Retinal Stimulator
Funder
National Health and Medical Research Council
Funding Amount
$998,194.00
Summary
Retinal degenerative conditions are the leading cause of blindness in developed nations, with over 200 million people afflicted worldwide. Our group has pioneered a minimally-invasive therapeutic stimulator that can arrest retinal degeneration without blocking vision. We are now ready to perform the prerequisite translational studies to develop and test a human-grade device. The ultimate goal is to be the first to develop a commercial therapeutic stimulator that protects against vision loss.